Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan

被引:63
作者
Sasaki, H
Manabe, A
Kojima, S
Tsuchida, M
Hayashi, Y
Ikuta, K
Okamura, J
Koike, K
Ohara, A
Ishii, E
Komada, Y
Hibi, S
Nakahata, T
机构
[1] Kawasaki Kyodo Hosp, Dept Pediat, Kawasaki Ku, Kawasaki, Kanagawa 2100833, Japan
[2] Univ Tokyo, Inst Med Sci, Tokyo, Japan
[3] Nagoya Univ, Sch Med, Dept Pediat, Nagoya, Aichi 466, Japan
[4] Childrens Hosp, Ibaraki, Osaka, Japan
[5] Univ Tokyo, Sch Med, Dept Pediat, Tokyo 113, Japan
[6] Yokohama City Univ, Sch Med, Dept Blood Transfus, Yokohama, Kanagawa 232, Japan
[7] Shinshu Univ, Sch Med, Dept Pediat, Matsumoto, Nagano 390, Japan
[8] Mie Univ, Sch Med, Dept Pediat, Tsu, Mie, Japan
[9] Kyoto Prefectural Univ, Sch Med, Dept Pediat, Kyoto 606, Japan
[10] Kyoto Univ, Sch Med, Dept Pediat, Kyoto 606, Japan
关键词
myelodysplastic syndrome; children; clinical features; predisposing conditions; cytogenetics; prognosis;
D O I
10.1038/sj.leu.2402271
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We report a retrospective analysis of children with myelodysplastic syndrome (MDS) diagnosed between 1990 and 1997 in Japan. In total, 189 patients were enrolled: 122 cases of primary MDS (26 RA, 18 RAEB, 25 RAEBt, 53 CMML/JMML), 24 cases with constitutional predisposition to MDS, and 43 cases of therapy-related MDS (t-MDS). The frequency of pediatric MDS was estimated to be 7.7% of all leukemias. Cytogenetic abnormalities were observed in 41% of primary MDS and 90% of t-MDS cases. The 4-year survival rate, estimated by Kaplan-Meier analysis, for primary RA was 78.9%, while other types of MDS and JMML had rates lower than 40%, and t-MDS showed an even more unfavorable prognosis. In primary MDS, the survival rate of patients with cytogenetic abnormalities was significantly lower. Among prognostic variables by IPSS, only the cytogenetic pattern was useful for predicting outcome in childhood MDS. There was no apparent advantage to chemotherapy for RA, and the survival rate In patients with primary RA, JMML, or t-MDS receiving stem cell transplantation was significantly higher. More precise designs of our diagnostic and classification systems, as well as therapeutic trials In large-scale prospective studies, are necessary for further Improvements in MDS outcome.
引用
收藏
页码:1713 / 1720
页数:8
相关论文
共 32 条
[11]  
GUBA SC, 1994, BLOOD, V83, P1486
[12]   A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada [J].
Hasle, H ;
Wadsworth, LD ;
Massing, BG ;
McBride, M ;
Schultz, KR .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (04) :1027-1032
[13]   MYELODYSPLASTIC SYNDROMES IN CHILDHOOD - A POPULATION BASED STUDY OF 9 CASES [J].
HASLE, H ;
JACOBSEN, BB ;
PEDERSEN, NT .
BRITISH JOURNAL OF HAEMATOLOGY, 1992, 81 (04) :495-498
[14]  
HASLE H, 1995, LEUKEMIA, V9, P1569
[15]   Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7 [J].
Hasle, H ;
Aricò, M ;
Basso, G ;
Biondi, A ;
Rajnoldi, AC ;
Creutzig, U ;
Fenu, S ;
Fonatsch, C ;
Haas, OA ;
Harbott, J ;
Kardos, G ;
Kerndrup, G ;
Mann, G ;
Niemeyer, CM ;
Ptoszkova, H ;
Ritter, J ;
Slater, R ;
Stary, J ;
Stollmann-Gibbels, B ;
Testi, AM ;
van Wering, ER ;
Zimmermann, M .
LEUKEMIA, 1999, 13 (03) :376-385
[16]   MONOSOMY-7 AND ACTIVATING RAS MUTATIONS ACCOMPANY MALIGNANT TRANSFORMATION IN PATIENTS WITH CONGENITAL NEUTROPENIA [J].
KALRA, R ;
DALE, D ;
FREEDMAN, M ;
BONILLA, MA ;
WEINBLATT, M ;
GANSER, A ;
BOWMAN, P ;
ABISH, S ;
PRIEST, J ;
OSEAS, RS ;
OLSON, K ;
PADERANGA, D ;
SHANNON, K .
BLOOD, 1995, 86 (12) :4579-4586
[17]  
Lange BJ, 1998, BLOOD, V91, P608
[18]  
LeBeau MM, 1996, BLOOD, V88, P1930
[19]   Allogenic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: A report from the European Working Group on Myelodysplastic Syndrome in Childhood [J].
Locatelli, F ;
Niemeyer, C ;
Angelucci, E ;
BenderGotze, C ;
Burdach, S ;
Ebell, W ;
Friedrich, W ;
Hasle, H ;
Hermann, J ;
Jacobsen, N ;
Klingebiel, T ;
Kremens, B ;
Mann, G ;
Pession, A ;
Peters, C ;
Schmid, HJ ;
Stary, J ;
Suttorp, M ;
Uderzo, C ;
vantVeerKorthof, ET ;
Vossen, J ;
Zecca, M ;
Zimmermann, M .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :566-573
[20]  
Locatelli F, 1996, BONE MARROW TRANSPL, V18, P63